BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $19.6364.

Several research analysts recently issued reports on BCRX shares. Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Evercore initiated coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price objective on the stock. HC Wainwright boosted their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Royal Bank Of Canada cut their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the transaction, the insider owned 400,703 shares in the company, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BioCryst Pharmaceuticals by 6.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock worth $1,019,000 after buying an additional 8,517 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 49.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock worth $14,490,000 after buying an additional 640,704 shares in the last quarter. Caxton Associates LLP acquired a new position in BioCryst Pharmaceuticals during the first quarter worth about $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in BioCryst Pharmaceuticals by 11.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after buying an additional 47,355 shares during the period. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $9.80 on Tuesday. The stock has a market capitalization of $2.46 billion, a P/E ratio of 8.17 and a beta of 0.73. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.31. The company’s fifty day moving average is $7.55 and its two-hundred day moving average is $7.44.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.07 by $1.05. The company had revenue of $163.28 million during the quarter, compared to analysts’ expectations of $151.32 million. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The business’s revenue was up 209.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.13) EPS. Sell-side analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.